Trial Profile
Feasibility and safety study of apatinib mesylate in combination with s-1 for neoadjuvant treatment of colorectal cancer and postoperative management of s-1
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Gimeracil/oteracil/tegafur
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jan 2018 New trial record